3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Classical hematology
1
CNS
1
Conditions
Urinary Tract Infections
1
Staphylococcal Infections
1
Spasm
1
Sleep Initiation and Maintenance Disorders
1
Sepsis
1
Seizures
1
Schizophrenia, Treatment-Resistant
1
Schizophrenia
1
Retinitis
1
Renal Insufficiency, Chronic
1
Pulmonary Arterial Hypertension
1
Pneumonia
1
Pain
1
Neutropenia
1
Migraine Disorders
1
Menorrhagia
1
Meningitis, Bacterial
1
Meningitis
1
Intraabdominal Infections
1
Influenza, Human
1
Inflammation
1
Infections
1
Hypokalemia
1
Hypertension
1
Hyperaldosteronism
1
Herpes Simplex
1
Hemophilia A
1
Hemangioma, Capillary
1
Heart Failure
1
Heart Arrest
1
Interventions
Cyclophosphamide
956
Radiotherapy
847
Cisplatin
757
Gemcitabine
657
Carboplatin
603
Docetaxel
598
Paclitaxel
585
Bevacizumab
580
Fluorouracil
504
Oxaliplatin
458
Rituximab
453
Surveys and Questionnaires
449
Capecitabine
440
Dexamethasone
428
Doxorubicin
424
Etoposide
411
Irinotecan
389
Cytarabine
376
Filgrastim
369
pembrolizumab
328
Leucovorin
305
Nivolumab
296
fludarabine phosphate
294
Melphalan
288
Magnetic Resonance Spectroscopy
280
Peripheral Blood Stem Cell Transplantation
279
Blood Specimen Collection
279
Methotrexate
276
Lenalidomide
276
Cetuximab
270
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
OTHER
×
Lurasidone Hydrochloride
×
Clear all
NCT01431326
2023-09-06
PTN_POPS
Duke University
Completed
3,520 enrolled